Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00064974 | Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes | PHASE2 | COMPLETED | 215 | — | — | Jun 1, 2003 | Feb 1, 2007 | Apr 4, 2013 | 119 | United States, Australia +13 |
| Arm | Type | Description |
|---|---|---|
| CC-5013 | EXPERIMENTAL | CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles) |
| Name | Type | Description |
|---|---|---|
| CC-5013 | DRUG | CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles) |
Inclusion Criteria: * Must understand and voluntarily sign an informed consent form. * Age ≥ 18 years at the time of signing the informed consent form. * Must be able to adhere to the study visit schedule and other protocol requirements. * Diagnosis of low - or intermediate-1-risk IPSS (Appendix II...